Literature DB >> 28586466

Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands.

Venetia Qendri1, Johannes A Bogaards1,2, Johannes Berkhof1.   

Abstract

Background: Uptake of human papillomavirus (HPV) vaccine among girls in the Dutch immunization program has plateaued at around 60%. Vaccinating boys may be an appealing complementary strategy for the prevention of HPV-related diseases, especially since tender negotiations and reduced dosing schemes have driven down the cost of vaccination.
Methods: We expanded a previously published Bayesian synthesis framework to account for all vaccine type-related cancers and herd immunity effects from vaccinating girls and boys. We evaluated the efficiency of vaccinating boys relative to increasing vaccine uptake among girls and assessed the cost-effectiveness of a sex-neutral program.
Results: Vaccinating 40% of boys along with 60% of girls yielded the same gain in life-years (LYs) as increasing the uptake in girls from 60% to 80%. The incremental cost-effectiveness ratio (ICER) of vaccinating boys was €9134/LY (95% credible interval [CrI], €7323/LY-€11231/LY) under 3% discounting. The ceiling vaccination costs at which the ICER remained below the per capita gross domestic product threshold was €240 (95% CrI, €200-€280) per vaccinated boy. If girls' uptake increased to 90%, the ceiling costs decreased to €70 (95% CrI, €40-€100) per vaccinated boy. Conclusions: Vaccinating boys along with girls is only modestly less efficient than increasing uptake among girls and highly likely to be cost-effective under current vaccine costs and uptake in the Netherlands.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Netherlands; cost-effectiveness analysis; human papillomavirus vaccines; sex-neutral vaccination; tender procedure

Mesh:

Substances:

Year:  2017        PMID: 28586466     DOI: 10.1093/infdis/jix272

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

Review 1.  Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses.

Authors:  Mireia Diaz; Silvia de Sanjosé; F Xavier Bosch; Laia Bruni
Journal:  Rep Pract Oncol Radiother       Date:  2018-04-26

2.  A qualitative study of parental associations and beliefs regarding the HPV vaccination for Dutch boys.

Authors:  Judith R Venderbos; Renske Eilers; Hein de Vries; Kim van Zoonen
Journal:  BMC Public Health       Date:  2022-06-14       Impact factor: 4.135

3.  Pricing of HPV vaccines in European tender-based settings.

Authors:  Venetia Qendri; Johannes A Bogaards; Johannes Berkhof
Journal:  Eur J Health Econ       Date:  2018-07-26

4.  Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.

Authors:  Petra J Woestenberg; Johannes A Bogaards; Audrey J King; Suzan Leussink; Marianne Ab van der Sande; Christian Jpa Hoebe; Birgit Hb van Benthem
Journal:  Int J Cancer       Date:  2018-12-21       Impact factor: 7.396

Review 5.  Vaccine Prices: A Systematic Review of Literature.

Authors:  Rabia Hussain; Nadeem Irfan Bukhari; Anees Ur Rehman; Mohamed Azmi Hassali; Zaheer-Ud-Din Babar
Journal:  Vaccines (Basel)       Date:  2020-10-29

6.  Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer.

Authors:  Federica Inturrisi; Birgit I Lissenberg-Witte; Nienke J Veldhuijzen; Johannes A Bogaards; Guglielmo Ronco; Chris J L M Meijer; Johannes Berkhof
Journal:  Int J Cancer       Date:  2020-07-28       Impact factor: 7.396

7.  Potential effectiveness of prophylactic HPV immunization for men who have sex with men in the Netherlands: A multi-model approach.

Authors:  Johannes A Bogaards; Sofie H Mooij; Maria Xiridou; Maarten F Schim van der Loeff
Journal:  PLoS Med       Date:  2019-03-04       Impact factor: 11.069

8.  HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control.

Authors:  Karen Canfell; Jane J Kim; Shalini Kulasingam; Johannes Berkhof; Ruanne Barnabas; Johannes A Bogaards; Nicole Campos; Chloe Jennett; Monisha Sharma; Kate T Simms; Megan A Smith; Louiza S Velentzis; Marc Brisson; Mark Jit
Journal:  Papillomavirus Res       Date:  2019-09-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.